Novel drug targets in clinical development for heart failure

European Journal of Clinical Pharmacology

Volumn 70, Issue 7, 2014, Pages 765-774

  George, Melvin ^a   Rajaram, Muthukumar ^a   Shanmugam, Elangovan ^a   VijayaKumar, Thangavel Mahalingam ^a  

^a SRM INSTITUTE OF SCIENCE AND TECHNOLOGY   (India)

Author keywords

Heart failure; Istaroxime; New drugs; Omecamtiv mecarbil; Relaxin; Targets

Indexed keywords

2,3,4,5 TETRAHYDRO 7 METHOXY 4 METHYL 1,4 BENZOTHIAZEPINE; 3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID PLUS VALSARTAN; 4 [3 (4 BENZYL 1 PIPERIDINYL)PROPIONYL] 2,3,4,5 TETRAHYDRO 7 METHOXY 1,4 BENZOTHIAZEPINE; ALADORIAN; ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR ALPHA; BOSENTAN; CINACIGUAT; COMPLEMENTARY DNA; DIGOXIN; ENALAPRIL; ISTAROXIME; MEMBRANE METALLOENDOPEPTIDASE; MYOSIN ADENOSINE TRIPHOSPHATASE; NEU DIFFERENTIATION FACTOR; NEW DRUG; OMECAMTIV MECARBIL; PLACEBO; RECOMBINANT NEUREGULIN 1BETA; RECOMBINANT RELAXIN; RENIN INHIBITOR; RIOCIGUAT; RYANODINE RECEPTOR; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SERELAXIN; SILDENAFIL; TOLVAPTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; URODILATIN; CARDIOVASCULAR AGENT;

ACUTE HEART FAILURE; CALCIUM TRANSPORT; CARDIOVASCULAR MORTALITY; CHRONIC DISEASE; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME ACTIVATION; ENZYME INHIBITION; FOLLOW UP; GENE THERAPY; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE REMODELING; HEMODYNAMIC PARAMETERS; HIGH THROUGHPUT SCREENING; HOSPITAL READMISSION; HUMAN; HYPERTENSION; HYPONATREMIA; HYPOTENSION; KIDNEY FUNCTION; LOW DRUG DOSE; MOLECULE; NAUSEA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPEATED DRUG DOSE; REVIEW; SARCOPLASMIC RETICULUM; SURVIVAL; TREATMENT OUTCOME; ANIMAL; DRUG DESIGN; DRUG EFFECTS; HEART MUSCLE; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOVASCULAR AGENTS; DRUG DESIGN; HEART FAILURE; HUMANS; MOLECULAR TARGETED THERAPY; MYOCARDIUM; SIGNAL TRANSDUCTION;

EID: 84903463128     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-014-1671-4     Document Type: Review

References (83)

1. Heart Failure. http://www.clevelandclinicmeded.com/medicalpubs/ diseasemanagement/cardiology/heart-failure/.Accessed 16 Sep 2013
2. Bui AL, Horwich TB, Fonarow GC (2011) Epidemiology and risk profile of heart failure. Nat Rev Cardiol 8:30-41
3. WRITING GROUPMEMBERS, Lloyd-Jones D, Adams RJ, Brown TM et al (2010) Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 121:e46-e215
4. Nieminen MS, Brutsaert D, Dickstein K et al (2006) EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 27:2725-2736 (Pubitemid 44729876)
5. Norton C, Georgiopoulou VV, Kalogeropoulos AP, Butler J (2011) Epidemiology and cost of advanced heart failure. Prog Cardiovasc Dis 54:78-85
6. Ferrandi M, Barassi P, Tadini-Buoninsegni F et al (2013) Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition. Br J Pharmacol 169:1849-1861
7. Micheletti R, Mattera GG, Rocchetti M et al (2002) Pharmacological profile of the novel inotropic agent (E, Z)-3-((2-aminoethoxy)imino)androstane- 6,17-dione hydrochloride (PST2744). J Pharmacol Exp Ther 303:592-600 (Pubitemid 35231230)
8. Khan H, Metra M, Blair JEA et al (2009) Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes? Heart Fail Rev 14:277-287
9. Blair JEA, Macarie C, Ruzyllo W et al (2008) Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial. Am J Ther 15:231-240
10. Shah SJ, Blair JEA, Filippatos GS et al (2009) Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial. Am Heart J 157:1035-1041
11. Aditya S, Rattan A (2012) Istaroxime: A rising star in acute heart failure. J Pharmacol Pharmacother 3:353-355
12. Garg V, Frishman WH (2013) A newapproach to inotropic therapy in the treatment of heart failure: cardiac myosin activators in treatment of HF. Cardiol Rev 21:155-159
13. Malik FI, Morgan BP (2011) Cardiac myosin activation part 1: from concept to clinic. J Mol Cell Cardiol 51:454-461
14. Meijs MFL, Asselbergs FW, Doevendans PA (2012) Omecamtiv mecarbil: a promising new drug in systolic heart failure. Eur J Heart Fail 14:232-233
15. Teerlink JR, Clarke CP, Saikali KG et al (2011) Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet 378:667-675
16. Cleland JGF, Teerlink JR, Senior R et al (2011) The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet 378:676-683
17. Avanzas P, Bayes-Genis A, de Isla LP, Sanchis J, Heras M (2013) Summary of the Clinical Studies Reported in the European Society of Cardiology Congress 2013 (31 August - 4 September, 2013, Amsterdam, The Netherlands). Rev Esp Cardiol Engl Ed 66: 879.e1-879.e9
18. Clinical Trials.gov http://clinicaltrials.gov/ct2/show/NCT01786512?term= omecamtiv+mecarbil&rank=4.Accessed 17 March 2014
19. Cernaro V, Lacquaniti A, Lupica R, et al (2013) Relaxin: New Pathophysiological Aspects and Pharmacological Perspectives for an Old Protein. Med Res Rev
20. Teichman SL, Unemori E, Teerlink JR, Cotter G, Metra M (2010) Relaxin: review of biology and potential role in treating heart failure. Curr Heart Fail Rep 7:75-82
21. Teerlink JR, Metra M, Felker GM et al (2009) Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 373:1429-1439
22. Metra M, Cotter G, Davison BA et al (2013) Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 61:196-206
23. Novartis to request re-examination of serelaxin (RLX030) in acute heart failure (AHF) for conditional marketing authorization in EU. http://www.novartis.com/newsroom/media-releases/en/2014/1756879.shtml. Accessed 17 March 2014
24. Edwards BS, Zimmerman RS, Schwab TR, Heublein DM, Burnett JC Jr (1988) Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res 62:191-195 (Pubitemid 18041941)
25. Saito Y (2010) Roles of atrial natriuretic peptide and its therapeutic use. J Cardiol 56:262-270
26. Ishikawa C, Tsutamoto T, Wada A et al (2005) Inhibition of aldosterone and endothelin-1 by carperitide was attenuated with more than 1 week of infusion in patients with congestive heart failure. J Cardiovasc Pharmacol 46:513-518 (Pubitemid 41407582)
27. Hayashi M, Tsutamoto T, Wada A et al (2001) Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 37:1820-1826 (Pubitemid 32499965)
28. Shono M, Yoshimura M, Nakayama M et al (2007) Predominant effect of A-type natriuretic peptide on reduction of oxidative stress during the treatment of patients with heart failure. Circ J Off J Jpn Circ Soc 71:1040-1046 (Pubitemid 46998017)
29. Liang F, O'Rear J, Schellenberger U et al (2007) Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 49:1071-1078 (Pubitemid 46349497)
30. Chen HH, Glockner JF, Schirger JA, Cataliotti A, Redfield MM, Burnett JC Jr (2012) Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide. J Am Coll Cardiol 60:2305-2312
31. Suwa M, Seino Y, Nomachi Y, Matsuki S, Funahashi K (2005) Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the "real world" of therapy. Circ J Off J Jpn Circ Soc 69:283-290 (Pubitemid 40410182)
32. Nomura F, Kurobe N, Mori Y et al (2008) Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: Carperitide Effects Observed Through Monitoring Dyspnea in Acute Decompensated Heart Failure Study. Circ J Off J Jpn Circ Soc 72:1777-1786
33. Hata N, Seino Y, Tsutamoto T et al (2008) Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study. Circ J Off J Jpn Circ Soc 72:1787-1793
34. Sezai A, Hata M, Niino T et al (2010) Continuous low-dose infusion of human atrial natriuretic peptide in patients with left ventricular dysfunction undergoing coronary artery bypass grafting: the NU-HIT (Nihon University working group study of low-dose Human ANP Infusion Therapy during cardiac surgery) for left ventricular dysfunction. J Am Coll Cardiol 55:1844-1851
35. Selby VN, Teerlink JR (2013) What's new in the treatment of acute heart failure? Curr Cardiol Rep 15:393
36. Mitrovic V, Seferovic PM, Simeunovic D et al (2006) Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J 27:2823-2832 (Pubitemid 44871466)
37. Lüss H, Mitrovic V, Seferovic PM et al (2008) Renal effects of ularitide in patients with decompensated heart failure. Am Heart J 155:1012.e1-8
38. Efficacy and Safety of Ularitide for the Treatment of Acute Decompensated Heart Failure - Full Text View - ClinicalTrials.gov.http://www.clinicaltrials. gov/ct2/show/NCT01661634?term=TRUE+AHF&rank=1.Accessed 24 Sep 2013
39. Kushnir A, Marks AR (2010) The ryanodine receptor in cardiac physiology and disease. Adv Pharmacol San Diego Calif 59:1-30
40. Aronson D, Krum H (2012) Novel therapies in acute and chronic heart failure. Pharmacol Ther 135:1-17
41. Shan J, Betzenhauser MJ, Kushnir A et al (2010) Role of chronic ryanodine receptor phosphorylation in heart failure and β-adrenergic receptor blockade in mice. J Clin Invest 120:4375-4387
42. Sacherer M, Sedej S, Wakuła P et al (2012) JTV519 (K201) reduces sarcoplasmic reticulum Ca2+ leak and improves diastolic function in vitro in murine and human non-failing myocardium. Br J Pharmacol 167:493-504
43. Lehnart SE, Mongillo M, Bellinger A et al (2008) Leaky Ca2+ release channel/ryanodine receptor 2 causes seizures and sudden cardiac death in mice. J Clin Invest 118:2230-2245
44. http://www.controlled-trials.com/ISRCTN14227980. Accessed 17 March 2014
45. Sawyer DB, Caggiano A (2011) Neuregulin-1β for the treatment of systolic heart failure. J Mol Cell Cardiol 51:501-505
46. Zhao YY, Sawyer DR, Baliga RR et al (1998) Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 273:10261-10269 (Pubitemid 28227629)
47. Li B, Zheng Z, Wei Y et al (2011) Therapeutic effects of neuregulin-1 in diabetic cardiomyopathy rats. Cardiovasc Diabetol 10:69
48. Liu X, Gu X, Li Z et al (2006) Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol 48:1438-1447 (Pubitemid 44436803)
49. Jabbour A, Hayward CS, Keogh AM et al (2011) Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. Eur J Heart Fail 13:83-92
50. Gao R, Zhang J, Cheng L et al (2010) A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebocontrolled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J Am Coll Cardiol 55:1907-1914
51. Valluri A, Struthers AD, Lang CC (2013) Novel Blockers of the Renin-Angiotensin-Aldosterone System in Chronic Heart Failure. Curr Heart Fail Rep(Nov 15)
52. McMurray JJV, Pitt B, Latini R, Maggioni AP et al (2008) Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 1:17-24
53. Solomon SD, Shin SH, Shah A et al (2011) Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J 32:1227-1234
54. Gheorghiade M, Böhm M, Greene SJ et al (2013) Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA J Am Med Assoc 309:1125-1135
55. Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbi-mortality in Patients With Chronic Heart Failure - Full Text View - ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT00853658?term= aliskiren+AND+heart+failure&rank=2. Accessed 17 Mar 2014
56. Abstract 19378: First Experience with Concomitant AT1 and Neprilysin (NEP 24.11) Inhibition with LCZ696 in Patients with Chronic Heart Failure - Kobalava et al. 122 (10021): A19378 - Circulation. http://circ.ahajournals.org/cgi/ content/meeting-abstract/122/21-MeetingAbstracts/A19378.Accessed 14 March 2014
57. Solomon SD, Zile M, Pieske B et al (2012) The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 380:1387-1395
58. McMurray JJV, Packer M, Desai AS et al (2013) Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensinconverting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 15:1062-1073
59. Ather S, Respress JL, Li N, Wehrens XHT (2013) Alterations in ryanodine receptors and related proteins in heart failure.Biochim Biophys Acta
60. Bers DM (2008) Calcium cycling and signaling in cardiac myocytes. Annu Rev Physiol 70:23-49
61. Jessup M, Greenberg B, Mancini D et al (2011) Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 124:304-313
62. Zsebo K, Yaroshinsky A, Rudy JJ et al (2014) Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res 114:101-108
63. A Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure - Full Text View - ClinicalTrials.gov .http://www.clinicaltrials. gov/ct2/show/study/NCT01643330?term=CUPID+study&rank=4&show-locs=Y#locn. Accessed 17 Mar 2014.
64. Niederseer D, Thaler CW, Niederseer M, Niebauer J (2013) Mismatch between heart failure patients in clinical trials and the real world. Int J Cardiol
65. Van Spall HGC, Toren A, Kiss A, Fowler RA (2007) Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA J Am Med Assoc 297:1233-1240 (Pubitemid 46465731)
66. Collins SP, Levy PD, Lindsell CJ et al (2009) The rationale for an acute heart failure syndromes clinical trials network. J Card Fail 15: 467-474
67. McDonagh TA, Komajda M, Maggioni AP et al (2009) Clinical trials in acute heart failure: simpler solutions to complex problems. Consensus document arising from a European Society of Cardiology cardiovascular round-table think tank on acute heart failure. Eur J Heart Fail 13:1253-1260
68. Search of: istaroxime - List Results - ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/results/displayOpt?flds=a&flds=b&flds= f&submit-fld-opt=on&term=istaroxime&show-flds=Y. Accessed 19 Sep 2013
69. Search of: omecamtiv mecarbil - List Results - ClinicalTrials.gov.http:// www.clinicaltrials.gov/ct2/results?term=omecamtiv+mecarbil&Search=Search. Accessed 19 Sep 2013
70. Search of: carperitide - List Results - ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/results?term=carperitide&Search=Search. Accessed 19 Sep 2013
71. Search of: relaxin - List Results - ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/results?term=relaxin&Search=Search. Accessed 19 Sep 2013
72. Search of: cinaciguat - List Results - ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/results?term=cinaciguat&Search=Search. Accessed 19 Sep 2013
73. Search of: SERCA2a - List Results - ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/results?term=SERCA2a&Search=Search. Accessed 19 Sep 2013
74. Cooper TJ, Guazzi M, Al-Mohammad A et al (2013) Sildenafil in Heart Failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial: rationale and design. Eur J Heart Fail 15:119-122
75. Mylona P, Cleland JG (1999) Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net Editorial Team. Eur J Heart Fail 1:197-200 (Pubitemid 30186712)
76. Handoko ML, de Man FS, Vonk-Noordegraaf A (2011) The rise and fall of endothelin receptor antagonists in congestive heart failure. Eur Respir J 37:484-485
77. Felker GM, Benza RL, Chandler AB et al (2003) Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 41:997-1003 (Pubitemid 36315544)
78. Triposkiadis F, Parissis JT, Starling RC, Skoularigis J, Louridas G (2009) Current drugs and medical treatment algorithms in the management of acute decompensated heart failure. Expert Opin Investig Drugs 18:695-707
79. Valania G, Singh M, Slawsky MT (2011) Targeting hyponatremia and hemodynamics in acute decompensated heart failure: is there a role for vasopressin antagonists? Curr Heart Fail Rep 8:198-205
80. Teerlink JR, Iragui VJ, Mohr JP et al (2012) The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patientswith acute heart failure and renal impairment: findings from PROTECT. Drug Saf Int J Med Toxicol Drug Exp 35:233-244
81. Gheorghiade M, Greene SJ, Filippatos G et al (2012) Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur J Heart Fail 14:1056-1066
82. Press Announcements>FDA approves Adempas to treat pulmonary hypertension. http://www.fda.gov/newsevents/newsroom/pressannouncements/ ucm370866.htm. Accessed 17 March 2014.
83. Hartog JWL, Willemsen S, van Veldhuisen DJ et al (2011) Effects of alagebrium, an advanced glycationendproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. Eur J Heart Fail 13:899-908